UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 10-QSB

 

 

[X]            QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ended March 31, 2008

 

OR

 

[  ]             TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.  

 

For the transition period from ______ to ______.

 

 

 

Check whether the  issuer (1) filed all reports required by Section 13 or 15(d) of the  Exchange Act during the  past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past  90 days.    Yes [X] No [ ]

 

 State the number by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ] No [X]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common equity as of the latest practicable date:  9,803,366 shares of Common Stock, no par value, as of May 9, 2008.

 

Transitional Small Business Disclosure Format:        Yes [  ] No [X]

 

-1-

 

 

 

 

 

 

Item 1.      Financial Statements

 

 

 

 

 

 

 

-2-

 

 

 

 

 

See notes to consolidated financial statements.

 

 

 

 

-3-

 

 

 

 

 

 

 

 

 

 

See notes to consolidated financial statements.

 

 

 

 

 -4-

 

 

 

 

 

 

 

 

 

 

 

 

 

See notes to consolidated financial statements.

 

 

-5-

 

 

 

 

 

 

PRO-DEX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

NOTE 1.         BASIS OF PRESENTATION

 

The accompanying unaudited consolidated financial statements of Pro-Dex, Inc. (“we”, “us”, “our”, “Pro-Dex” or the "Company") have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Regulation S-B. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. These financial statements should be read in conjunction with the audited financial statements presented in our Annual Report for the fiscal year ended June 30, 2007.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included. The results of operations for such interim periods are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-KSB for the year ended June 30, 2007.

 

NOTE 2.         INVENTORIES

 

            Inventories are stated at the lower of cost (the first-in, first-out method) or market and consist of the following:

 

 

Due to the change in product mix with a greater amount of sales of custom medical devices with a reduced number of final part numbers, we changed the method for establishing the reserve for slow moving and obsolete items as of the quarter ended March 31, 2008.  This change is expected to better align the inventory reserve with the marketability of the inventory components.   

 

The prior method calculated the reserve by comparing the quantity of an item on hand with its 12-month sales history.  If inventory on hand for a specific part exceeded an estimated 24 months of usage, between 20% and 100% of its value may have been included in the inventory reserve.  The actual percentage reserved depended on the total quantity on hand, its sales history and expected near-term sales prospects.  The method was changed in two ways.  First, the inventory’s estimated 12-month usage is the greater of the prior 12-months sales history or the firm orders for future shipments.  The second change is to reserve 100% of an item’s value of the inventory on hand that exceeds an estimated 12 months of usage.  The calculation method change had an effect of increasing the inventory reserve at March 31, 2008 by $301,000 to $1,119,000.  

 

 

 

 

-6-

 

 

 

 

 

 

 

 

 

NOTE 3.         WARRANTY

 

The warranty reserve is based on historical costs of warranty repairs and expected future identifiable warranty expenses.  As of March 31, 2008 we carried a warranty reserve of $784,000 which was comprised of $38,000 for future warranty expenses related to products that are currently in the process of being repaired, $704,000 for future warranty expenses related to products that are still in the field, and $42,000 for our legacy dental and industrial products.  Warranty expenses are reflected in the financial statements in cost of sales (“COS”).  The total warranty expense reflected in the cost of sales for the quarter ended March 31, 2008 was $426,000 and for the nine-months ended March 31, 2008 was $1,058,000.  The warranty accrual and expenses for the three and nine-months ended March 31, 2008 and 2007 are presented below:

 

 

 

 

 

 

NOTE 4.         NET INCOME PER SHARE

            The following table reconciles the weighted average shares outstanding for basic and diluted net income per share for the periods indicated.

 

-7-

 

 

 

 

NOTE 5.         CREDIT FACILITIES

 

On November 1, 2007, our existing credit facility with Wells Fargo was replaced with an expanded facility with a total borrowing capacity of $6,562,500.  Included in the increase is an increase in the credit line borrowing availability from $2,000,000 to $4,000,000.  The credit line’s terms require monthly interest payments at the prime rate of interest (5.25% at March 31, 2008); or LIBOR (2.6% at March 31, 2008 plus 1.75%), at our discretion, based on outstanding borrowings.  The total effective interest rate at March 31, 2008 for borrowings on the credit line was 4.5%.  The credit facility expires on November 1, 2009.  In addition to the credit line, a term commitment is available for borrowings for amounts up to $2,000,000.  We can take advances against this commitment through November 1, 2008, at which time the outstanding borrowings against this commitment will be converted to a term loan, to be amortized and repaid over 60 months. The term commitment’s terms require monthly interest payments at the prime rate of interest; or LIBOR plus 2.0%, at our discretion, based on outstanding borrowings.  It is anticipated that the borrowings from the term commitment will be used for construction financing of tenant improvements for our new Irvine, California facility.  The term loan that was entered into in January 2006 to finance the Astromec purchase remains in place.  As of March 31, 2007, there was a principal balance on this term loan of $458,333 which is required to be fully paid-off in January 2010, in accordance with its amortization schedule.  The term loan’s terms require monthly interest payments at the prime rate of interest; or LIBOR plus 2.5%, at our discretion, based on outstanding borrowings, with no minimum interest charge.  The total effective interest rate at March 31, 2008 for borrowings on term loan was 5.25%.  All assets of the Company except our Carson City land and building secure the outstanding borrowings from Wells Fargo. There was $500,000 borrowed under the terms of the credit line and nothing borrowed against term commitment facility as of March 31, 2008.  The total eligible additional borrowing capacity at March 31, 2008 was $5,500,000.

 

-8-

 

 

 

 

 

In March 2006, we entered into a 10-year mortgage with Union Bank of California for $1,650,000.  Its terms require monthly interest payments at a fixed rate of 6.73% based on outstanding borrowings.  The principal payments on the mortgage note are based on a 25-year amortization of the note and are $11,000 per month beginning May 1, 2006.  The outstanding borrowings are secured by our Carson City land and building.  There was approximately $1,598,000 outstanding balance under the terms of this mortgage as of March 31, 2008. 

 

There are certain financial and non-financial covenants that we must meet to be in compliance with the terms of the Wells Fargo credit facility (which includes the term loan and the line of credit), as amended, and the Union Bank mortgage.  At March 31, 2008, management believes that the Company was in compliance with all such covenants.           

 

NOTE 7.         INCOME TAXES

 

Deferred income taxes are provided on a liability method whereby deferred tax assets and liabilities are recognized for temporary differences.  Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.  We have tax credit carry forwards totaling $201,000 for state tax purposes that do not expire and can be carried forward indefinitely until fully utilized. 

 

            Significant management judgment is required in determining our provision for income taxes and the recoverability of our deferred tax asset.  Such determination is based on our estimates of future taxable income by jurisdiction in which we operate and the period over which our deferred tax assets will be recoverable.  In the event that actual results differ from these estimates or we adjust these estimates in future periods, we may need to establish a valuation allowance, which could result in a tax provision up to the carrying value of our deferred tax assets.

 

In July 2006, the FASB issued FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes,” (“FIN 48”), an interpretation of FASB Statement No. 109, “Accounting for Income Taxes,” (“FASB 109”). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with FASB 109. This Interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. The cumulative effect of applying FIN 48 is to be reported as an adjustment to the opening balance of retained earnings in the year of adoption.  As a result of the implementation of FIN 48, the Company recorded a decrease of $75,000 to retained earnings, an increase of $47,000 to net deferred income tax assets and an increase of $122,000 to income taxes payable as of July 1, 2007.

 

 

 

-9-

 

 

 

 

 

 

 

 

 

As of March 31, 2008, the Company has provided a liability for $110,000 of unrecognized tax benefits related to various federal and state income tax matters.  Of this total, $62,000 relates to R&D credits and would (i) reduce the Company’s income tax expense if recognized and (ii) result in a corresponding decrease in the Company’s effective tax rate.

 

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

 

           

Balance at July 1, 2007	$212,000
Additions based on tax positions related to the current year	0
Additions for tax positions of prior years	0
Reductions for tax positions of prior years	$102,000
Settlements	0
	-----------
Balance at March 31, 2008	$110,000

 

As of March 31, 2008, the Company had approximately $48,000 in accrued interest and penalties which is included as a component of the $110,000 unrecognized tax benefit noted above. The liability for the payment of interest and penalties has not changed during the nine months ended March 31, 2008. 

 

The Company and its subsidiary are subject to U.S. federal income tax and are currently under audit by the Internal Revenue Service for the years ended June 30, 2004 through June 30, 2006.  It is possible that the examination phase of the audit for these years may conclude in the next 12 months. The Company believes the appropriate provisions for all outstanding issues have been made for all years under audit.

 

            The Company and its subsidiary are subject to income tax of multiple state tax jurisdictions. The Company and its subsidiary state income tax returns are open to audit under the statute of limitations for the years ended June 30, 2003 through June 30, 2007. The company does not anticipate a significant change to the total amount of unrecognized tax benefits within the next 12 months.

 

NOTE 8.         SHARE-BASED COMPENSATION

 

Share-based compensation expense recognized under SFAS 123(R) for the three months ended March 31, 2008 and 2007 was $54,000 and $114,000, respectively, which was related to stock options and restricted stock grants in 2007 and 2008.  Share-based compensation expense reduced our results of operations as shown:

 

-10-

 

 

 

 

 

 

 

Share-based compensation expense recognized under SFAS 123(R) for the nine months ended March 31, 2008 and 2007 was $157,000 and $199,000, respectively, which was related to stock options and restricted stock grants in 2007 and 2008.  Share-based compensation expense reduced our results of operations as shown:

 

 

 

As of March 31, 2008, there was $124,258 of total unrecognized compensation cost related to 204,250 non-vested outstanding stock options with a per share weighted average value of $1.07.  The unrecognized expense is anticipated to be recognized on a straight-line basis over a weighted average period of 1.2 years.  The following is a summary of stock option activity in the nine months ending March 31:

 

	2008				2007
		Weighted- Average				Weighted- Average
Fixed Options	Shares	Exercise Price			Shares	Exercise Price
Outstanding at beginning of fiscal year (7/1)	1,038,500	$	1.60		1,204,316	$	1.68
Granted	101,000	1.50			411,000	1.41
Exercised	-	-			(110,000)	1.24
Forfeited	(30,000)	1.76			(205,000)	2.62
Outstanding at end of period (3/31)	1,109,500	$	1.59		1,300,316	$	1.49
Exercisable at end of period (3/31)	905,250	$	1.56		916,816	$	1.42
Weighted-average fair value per
Option granted during the period		$	0.79			$	1.30

 

 

The following table summarizes information regarding options outstanding and options exercisable at March 31, 2008:

 

		Options Outstanding						Options Exercisable
		Weighted- Average	Weighted- Average		Aggregate				Weighted- Average		Aggregate
Range of	Number	Remaining	Exercise		Intrinsic			Number	Exercise		Intrinsic
Exercise Price	Outstanding	Contractual Life	Price		Value			Outstanding	Price		Value
$0.42 to $0.81	260,000	4.0 years	$	0.70	$	216,200		260,000	$	0.70	$	216,200
$1.08 to $1.56	432,000	6.7 years	1.37		$	68,220		271,500	1.32		$	58,770
$1.74 to $2.18	242,500	4.0 years	2.04		$	-		228,750	2.05		$	-
$2.44 to $3.30	175,000	7.3 years	2.77		$	-		145,000	2.81		$	-
Total	1,109,500	5.5 years	$	1.58	$	284,420		905,250	$	1.56	$	274,970

 

 

 

-11-

 

 

 

 

Restricted Stock

 

The following is a summary of restricted share activity in the nine months ending March 31:

 

 

As of March 31, 2008, there was $225,000 of total unrecognized compensation cost related to 162,917 non vested outstanding restricted shares with a per share weighted average value of $1.38.  The unrecognized expense is anticipated to be recognized on a straight-line basis over a period of 1.9 years. 

 

Stock Warrants

 

At March 31, 2008, warrants to acquire 100,000 shares of common stock were outstanding. These warrants are fully vested, have a weighted-average exercise price of $1.25 and a weighted-average remaining life of 1.25 years. 

 

NOTE 9.         MAJOR CUSTOMERS

 

We had two major customers (defined as a customer that represents greater than 10% of the Company’s total revenues) in the nine months ended March 31, 2008 and 2007.  

 

 

NOTE 10.       COMMITMENTS AND CONTINGENCIES

 

Our manufacture and distribution of certain products involves a risk of legal action, and, from time to time, we are named as defendants in lawsuits. It is not reasonably possible to estimate the awards or damages, or the range of awards or damages, if any, we might incur in connection with such litigation.  Management is not aware of any material actual, pending or threatened litigation at this time.

 

 

-12-

 

 

 

 

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

COMPANY OVERVIEW

 

The following discussion and analysis provides information that the Company's management believes is relevant to an assessment and understanding of our results of operations and financial condition for each of the three and nine month periods ended March 31, 2008 and 2007, respectively.  This discussion should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included elsewhere in this Report. This Report contains certain forward-looking statements and information. The cautionary statements included herein should be read as being applicable to all related forward-looking statements wherever they may appear.  Our actual future results could differ materially from those discussed herein.  Our critical accounting policies relate to inventory valuation for slow moving items, impairment of goodwill, warranty reserves, and recoverability of deferred income taxes.

 

Except for the historical information contained herein, the matters discussed in this Quarterly Report on Form 10-QSB, including discussions of our product development plans, business strategies and market factors influencing our results, are forward-looking statements that involve certain risks and uncertainties. Actual results may differ from those anticipated by us as a result of various factors, both foreseen and unforeseen, including, but not limited to, our ability to continue to develop new products and increase systems sales in markets characterized by rapid technological evolution, consolidation within our target marketplace and among our competitors, and competition from larger, better capitalized competitors.  Many other economic, competitive, governmental and technological factors could impact our ability to achieve our goals.  Interested persons are urged to review the risks described herein, as well as in our other public disclosures and filings with the Securities and Exchange Commission.  We refer you to the risk factors and cautionary language contained in our reports filed with the Securities and Exchange Commission from time to time, including, but not limited to, those risks and uncertainties which may be listed in our Annual Report on Form 10-KSB.

 

Pro-Dex, Inc. (“Company,” “Pro-Dex”, “we,” “our,”, “us”), with operations in Irvine, California, Beaverton, Oregon and Carson City, Nevada, specializes in bringing speed to market in the development and manufacture of technology-based solutions that incorporate embedded motion control, miniature rotary drive systems and fractional horsepower DC motors, serving the medical, dental, semi-conductor, scientific research and aerospace markets. Pro-Dex's products are found in hospitals, dental offices, medical engineering labs, commercial and military aircraft, scientific research facilities and high tech manufacturing operations around the world. The company names of Micro Motors, Oregon Micro Systems, and Astromec are used for marketing purposes as brand names.

 

Pro-Dex’s principal headquarters changed April 28, 2008 and we are now located at 2361 McGaw Avenue, Irvine, California 92614 and our phone number also changed to 949-769-3200.  Our Internet address is www.pro-dex.com .  Our annual reports on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K, amendments to those reports and other SEC filings, are available free of charge through our website as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC.  In addition, our Code of Ethics and other corporate governance documents may be found on our website at the Internet address set forth above.  Our filings with the SEC may also be read and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549.  You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov .

 

 

 -13-

 

 

 

 

 

 

 

Description of Business

 

The majority of our revenue is derived from designing, developing and manufacturing rotary drive systems for the medical device and dental industries, motion control software and hardware for industrial and scientific applications and fractional horsepower DC motors for aerospace, medical and military applications. A large part of the revenue of the Company has been driven by developing and selling numerous types of private label rotary drive systems for use in dental, cranial, spinal, arthroscopic and orthopedic surgery.  The Company distributes its own line of pneumatic and electric dental hand pieces sold under the Micro Motors name utilizing a network of independent sales representatives across North America.  Other revenue sources include designing and manufacturing miniature pneumatic motors, fractional horsepower DC motors and motion control systems for industrial applications in the automotive, aerospace, and apparel industries.

 

All years relating to financial data herein shall refer to fiscal years ending June 30, unless indicated otherwise.

 

Company-funded research and development supports the development of generic rotary drive, motion control, and electric motor technology platforms.  Company-funded research and development projects are generally expected to convert to customer-funded projects within six to eighteen months.  Company funded project costs not associated with signed contracts or purchase orders are expensed as incurred.  In the three months ended March 31, 2008, $729,000 was expensed as research and development an increase of $65,000 from the $664,000 expensed in the three months ended March 31, 2007. 

 

We seek customer-funded projects to customize these platforms to specific customer requirements.  For customer-funded development projects, costs are capitalized and recognized as a cost of sales when specific deliverables within the development contracts are earned, matching the costs to the revenue. 

 

 

Customer-funded research and development fees increased in the quarter ended March 31, 2008 due to the initial work being completed on recently signed projectsr.  The results of customer-funded development work are intended to provide long-term exclusive manufacturing agreements and may provide the customer with the retention of the intellectual property developed.  The identity of our customers is generally protected by a non-disclosure agreement. 

 

The Company’s revenue is derived from five main customer types.  The proportion of total sales to each customer type and sales by location are noted in the tables below (unaudited):

 

 

-14-

 

 

 

 

 

 

	Three months Ended March 31,							Nine months Ended March 31,
Sales by customer type ($'000)	2008			2007				2008			2007
Dental	$	840	11%	$	1,466	25%		$	2,589	13%	$	3,653	23%
Medical	4,668		61%	2,488		42%		11,400		58%	6,340		40%
Industrial	835		11%	758		13%		2,466		13%	2,518		16%
Aerospace	739		10%	633		11%		1,718		9%	1,794		11%
Government, repairs and other	532		7%	571		10%		1,555		8%	1,475		9%
Total Sales	$	7,614	100%	$	5,916	100%		$	19,728	100%	$	15,780	100%

 

 

	Three months Ended March 31,							Nine months Ended March 31,
Sales by location ($'000)	2008			2007				2008			2007
Santa Ana	$	5,812	76%	$	4,034	68%		$	14,550	74%	$	10,060	64%
Beaverton	775		10%	1,007		17%		2,612		13%	3,068		19%
Carson City	1,027		13%	875		15%		2,566		13%	2,652		17%
Total Sales	$	7,614	100%	$	5,916	100%		$	19,728	100%	$	15,780	100%

 

Medical product sales represent the manufacture of products that utilize proprietary designs developed by us under exclusive design and supply agreements.  Our dental products are primarily sold to original equipment manufacturers and dental product distributors.  An independent dealer network markets our own branded line of dental products; including the Intraflow^TM dental anesthesia product we acquired the rights to in October 2005.  We also design and manufacture embedded multi-axis motion controllers used to regulate the motion of servo and stepper motors, predominantly for the factory automation, scientific research, and medical analysis equipment industries.  The controllers support the platforms for PCI, VME, ISA, and cPCI busses as well as stand-alone requirements.  In addition, we make and sell pneumatic motors for industrial applications that are marketed directly to end-users and through industrial supply distributors.  We added significant sales with the purchase of the assets of Astromec, Inc. and the establishment Pro-Dex Astromec, Inc. in January 2006.  Pro-Dex Astromec’s products include high reliability fractional horsepower DC motors designed for harsh environments, primarily for the aerospace and medical markets. 

 

We hold the following three independently verified certifications: ISO 9001:2000, ISO 13485 revised 1998, and Medical Device Directive 93\42\EEC Annex II company.

 

At the present time, we are generally able to fill orders within sixty (60) days.  At March 31, 2008, we had a backlog, including orders for delivery beyond 60 days, of $9.6 million compared with a backlog of $9.3 million at March 31, 2007 and $10.1 million at June 30, 2007.  We expect to ship most of our backlog in fiscal year 2008 and the remainder in fiscal year 2009.  The increased backlog compared to March 2007 and the decrease from June 2007 is due to normal fluctuations in the timing of receipt and shipment of orders.  We do not typically experience seasonal fluctuations in our new order bookings, but may experience variability in our new order bookings due to the timing of major new product launches.  Similarly, we do not typically experience seasonal fluctuations in our shipments and revenues. 

 

Change in Critical Accounting Estimates and Judgments

 

Due to the change in product mix with a greater amount of sales of custom medical devices with a reduced number of final part numbers, we changed the method for establishing the reserve for slow moving and obsolete items as of the quarter ended March 31, 2008.  This change is expected to better align the inventory reserve with the marketability of the inventory components.   

 

 

-15-

 

 

 

 

 

 

 

The prior method calculated the reserve by comparing the quantity of an item on hand with its 12-month sales history.  If inventory on hand for a specific part exceeded an estimated 24 months of usage, between 20% and 100% of its value may have been included in the inventory reserve.  The actual percentage reserved depended on the total quantity on hand, its sales history and expected near-term sales prospects.  The method was changed in two ways.  First, the inventory’s estimated 12-month usage is the greater of the prior 12-months sales history or the firm orders for future shipments.  The second change is to reserve 100% of an item’s value of the inventory on hand that exceeds an estimated 12 months of usage.  The calculation method change had an effect of increasing the inventory reserve at March 31, 2008 by $301,000 to $1,119,000.  

  

 

 

 

 

-16-

 

 

 

 

 

 

Results of Operations

 

For the Three-Month periods ended March 31, 2008 and 2007

 

            The following table sets forth the periods indicated and the percentage of net revenues represented by each item in our Consolidated Statements of Operations.

 

 

Net Sales.  Consolidated sales increased from $5,916,000 to $7,614,000 ($1,698,000 or 29%) for the quarter ended March 31, 2008 compared to the quarter ended March 31, 2007.  The increase was due to continued growth in medical product sales, shipped primarily from the Santa Ana facility, offsetting declines in revenues for the other product lines.    

 

Although selective price increases and decreases were implemented in response to market conditions, the majority of the sales changes for each product line are due primarily to changes in sales volume, not the effect of price changes.

 

Gross Profit and Gross Profit Percentage of Sales.  Our consolidated gross profit for the quarter ended March 31, 2008 increased $70,000 or 3% over the same quarter in the previous year due to the higher level of sales.  Gross profit as a percentage of sales decreased to 29% for the quarter ended March 31, 2008 compared to 36% for the quarter ended March 31, 2007. Gross profit margins were reduced approximately 4 margin points by the inventory reserve method change, another 1 margin point  for the sales mix shift away from software related industrial sales to medical sales, and 2 margin points for higher warranty cost as a percentage of sales due to the higher shipments of warranty related products.  Gross profit and gross profit as a percentage of sales were as follows:

 

 

 

-17-

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Costs (S, G&A).  Consolidated S, G & A expenses increased to $1,289,000 for the quarter ended March 31, 2008 from $1,141,000 for the quarter ended March 31, 2007.  The increase in selling expense is mainly due to higher labor and labor related costs ($66,000) offset primarily by lower advertising costs ($24,000). The increase in G & A costs was due to higher labor costs ($99,000) and costs associated with preparations for the upcoming facility move ($13,000).  As a percentage of sales, S, G&A expenses decreased to 17% of sales from 19% of sales for the quarters ended March 31, 2008 and 2007 respectively.  S, G&A costs were as follows:

 

 

 

Research and Development (R&D) Costs.  Company-funded research and development expenses increased $65,000 to $729,000 for the quarter ended March 31, 2008 from $664,000 for the quarter ended March 31, 2007, an increase of 10%.  The increase was due to approximately $109,000 in higher labor costs offset by a $52,000 reduction in independent research project costs as more projects were funded by customers as opposed to engineers working on company-funded projects.  As a percentage of sales, company-funded research & development expenses decreased to 10% of sales from 11% of sales for the quarters ended March 31, 2008 and 2007 respectively.  Company-funded research and development costs were as follows:

 

 

 

Operating Profit and Operating Profit Percentage of Sales.  Our consolidated operating profit for the quarter ended March 31, 2008 decreased to $208,000 compared to $351,000 for the same quarter in the previous year.  The decrease in operating profit was due to the effect of the inventory reserve increase.  Consequently, operating profit as a percentage of sales decreased to 3% for the quarter ended March 31, 2008 compared to 6% for the quarter ended March 31, 2007.  Operating profit and margin were as follows:

 

 

 

Royalties and Other Income.  We received $5,000 in royalty income in the three months ended March 31, 2008, compared to $5,000 in the same period during the prior year.  During the quarter ended March 31, 2008, we reversed $44,000 of the $48,000 in other income recorded in the three months ended December 31, 2007 due to the discovery of an error in the calculation associated with early and discounted payment of debt related to the Intravantage deferred payables.

 

Net Interest Expense.  Net interest expense for the quarter ended March 31, 2008 was $37,000 compared to $66,000 in the quarter ended March 31, 2007, due to the lower debt levels and lower market interest rates through the quarter ended March 31, 2008.

 

-18-

 

 

 

 

 

 

 

Income Tax (Benefit) Provision. Our estimated effective combined federal and state tax rate on income from operations for the quarter ended March 31, 2008 resulted in a 24% provision of earnings before tax compared to a 24% provision of earnings before tax for the quarter ended March 31, 2007.  The 2008 rate is reduced by a recalculation of the FIN 48 estimated tax and interest liability and the 2007 rate is reduced due to the use of estimated R&D state tax credits.

 

Net Income.  Our net income for the three months ended March 31, 2008 was $99,000 or $0.01 per share on a basic and diluted basis, as compared to a net income of $216,000 or $0.02 per share on a basic and diluted basis for the three months ended March 31, 2007.

 

For the Nine-Month periods ended March 31, 2008 and 2007

 

            The following table sets forth the periods indicated and the percentage of net revenues represented by each item in our Consolidated Statements of Operations.

 

(In Thousands)	Nine Months Ended March 31,
	2008			2007
Net sales:	$	19,728	100%	$	15,780	100%
Cost of sales	12,996		66%	10,274		65%
Gross Profit	6,732		34%	5,506		35%
Selling, general and administrative expenses	3,564		18%	3,145		20%
Research and development costs	1,939		10%	1,890		12%
Income (Loss) from Operations	1,229		6%	471		3%
Net interest and other expense	(91)		0%	(142)		-1%
Earnings before provision for income taxes	1,138		6%	329		2%
Provision for income taxes	409		2%	10		0%
Net income	$	729	4%	$	319	2%

 

 

Net Sales.  Consolidated net sales increased to $19,728,000 from $15,780,000 ($3,948,000 or 25%) for the nine months ended March 31, 2008, compared to the nine months ended March 31, 2007.  Increases in medical shipments by $5,060,000 more than offset the combined decreases in dental, industrial and aerospace shipments.

 

Gross Profit and Gross Profit Percentage of Sales.  Our consolidated gross profit for the nine months ended March 31, 2008 increased $1,226,000 or 22% over the same period in the previous year due to the higher sales levels of medical products.  Gross profit as a percentage of sales decreased to 34% for the nine months ended March 31, 2008 compared to 35% for the nine months ended March 31, 2007.  Gross profit margins were reduced 1.5 margin points by the change in inventory reserve calculation method.  This reduction was slightly offset by efficiency gains due to the higher sales levels.  Warranty costs represented approximately 5% of sales in each period.  Gross profit and gross profit as a percentage of sales were as follows:

 

 

-19-

 

 

 

 

 

 

 

 

Selling, General and Administrative Costs (S, G&A).  Consolidated S, G & A expenses increased 13% to $3,564,000 for the nine months ended March 31, 2008 from $3,145,000 for the nine months ended March 31, 2007.  The increase in selling expense is mainly due to higher labor and labor related costs ($204,000) offset primarily by lower advertising costs ($72,000) and bad debt expense ($90,000). The increase in G & A costs was due to higher labor and labor related costs ($305,000) and higher consulting expenses associated with the ongoing income tax audit, the adoption of FIN 48, and for implementation of the Sarbanes-Oxley financial controls documentation ($108,000).  These increases were offset by decreases in FAS 123 (R) costs, insurance and public relations.  As a percentage of sales, S, G&A expenses decreased to 18% of sales from 20% of sales.  S, G & A costs were as follows:

 

 

Research and Development (R&D) Costs.  Company-funded research and development expenses increased $49,000 to $1,939,000 for the nine months ended March 31, 2008 from $1,890,000 for the nine months ended March 31, 2007, an increase of 3%. The increase was due to approximately $117,000 in higher labor costs reduced by $43,000 reduction in independent research project costs as more projects were funded by customers as opposed to engineers working on company-funded projects   In addition, there was a $21,000 cost decrease in outside consulting expense during the quarter ended March 31, 2008 compared to the same period of the prior year.  Company-funded research and development costs were as follows:

 

Operating Profit and Operating Profit Percentage of Sales.  Our operating profit for the nine months ended March 31, 2008 increased to $1,229,000 compared to $471,000 for the same period in the previous year.  The increase in operating profit was due to the higher sales coupled with the controlled growth in S, G&A and research and development expenses.  Consequently, operating profit as a percentage of sales increased to 6% for the nine months ended March 31, 2008 compared to 3% for the nine months ended March 31, 2007.   Operating profit and margin were as follows:

 

 

 

-20-

 

 

 

 

 

 

 

Royalties and Other Income.  We received $25,000 in royalty payments in the nine months ended March 31, 2008, compared to $30,000 in royalty payments in the nine months ended March 31, 2007.  We recognized an additional $4,000 in income in the nine months ended March 31, 2008 for gains associated with early and discounted payment of debt related to the Intravantage deferred payables.

 

 

Net Interest Income/Expense.  Net interest expense for the nine months ending March 31, 2008 was $119,000 compared to net interest expense of $179,000 in the nine months ended March 31, 2007, due to lower debt levels and lower market interest rates through the current fiscal year.

 

Income Tax (Benefit) Provision. Our estimated effective combined federal and state tax rate on income from operations for the nine months ended March 31, 2008 resulted in a 36% provision of earnings before tax compared to a 3% provision of earnings before tax for the nine months ended March 31, 2007.  The difference in the 2007 rate is due to the use of state tax credits coupled with a retroactive reinstatement of the federal research and development credit of $64,000.  The reinstatement was for expenses incurred after March 31, 2005.

 

Net Income.  Our net income for the nine months ended March 31, 2008 was $729,000 or $0.08 per share on a basic and $0.07 per share on a diluted basis, as compared to a net income of $319,000 or $0.03 per share on a basic and diluted basis for the nine months ended March 31, 2007.          

 

 

 

 

 

 

 

 

 

 

-21-

 

 

 

 

 

 

 

Liquidity and Capital Resources

 

The following table presents selected financial information as of the end of the third quarters of fiscal 2008 and 2007 as well as of the year ended June 30, 2007:

 

¹ Working Capital = Ending Current Assets less Ending Current Liabilities.

² Tangible book value/common share = (Total shareholders’ equity – Net intangible asset (patents) - Goodwill) / (basic outstanding shares).

³ DSO = Ending Net Accounts Receivable balance / (Previous Quarter Sales / 91).

 

Our working capital at March 31, 2008 decreased to $5.7 million compared to $6.5 million at March 31, 2007 and $6.6 million at June 30, 2007.   The decrease was due to increased accrued expenses and accounts payable.  Cash flow provided by operations was $2,128,000 in the nine months ended March 31, 2008 compared to $298,000 for the nine months ended March 31, 2007.  Fiscal year 2008 cash was provided through continued profitability and improvements in accounts receivable levels and higher levels of accounts payable and accrued expenses.

 

On November 1, 2007, our existing credit facility with Wells Fargo was replaced with an expanded facility with a total borrowing capacity of $6,562,500.  Included in the increase is an increase in the credit line borrowing availability from $2,000,000 to $4,000,000.  The credit line’s terms require monthly interest payments at the prime rate of interest (5.25% at March 31, 2008); or LIBOR (2.6% at March 31, 2008) plus 1.75%, at our discretion, based on outstanding borrowings.  The total effective interest rate at March 31, 2008 for borrowings on the credit line was 4.5%.  The credit facility expires on November 1, 2009.  In addition to the credit line, a term commitment is available for borrowings for amounts up to $2,000,000.  We can take advances against this commitment through November 1, 2008, at which time the outstanding borrowings against this commitment will be converted to a term loan, to be amortized and repaid over 60 months. The term commitment requires monthly interest payments at the prime rate of interest; or LIBOR plus 2.0%, at our discretion, based on outstanding borrowings.  It is anticipated that the borrowings from the term commitment will be used for construction financing of tenant improvements for our new Irvine, California facility.  The term loan that was entered into in January 2006 to finance the Astromec purchase remains in place.  As of March 31, 2007, there was a principal balance on this term loan of $458,333 which is required to be fully paid-off in January 2010, in accordance with its amortization schedule.  The term loan requires monthly interest payments at the prime rate of interest; or LIBOR plus 2.5%, at our discretion, based on outstanding borrowings, with no minimum interest charge.  The total effective interest rate at March 31, 2008 for borrowings on term loan was 5.25%.  All assets of the Company except our Carson City land and building secure the outstanding borrowings from Wells Fargo. There was $500,000 borrowed under the terms of the credit line and nothing borrowed against term commitment facility as of March 31, 2008.  The total eligible additional borrowing capacity at March 31, 2008 was $5,500,000. 

-22-

 

 

 

 

 

 

 

 

At March 31, 2008, we had cash and cash equivalents of $529,000.  We believe that our cash and cash equivalents on hand, together with cash flows from operations, if any, and amounts available under the credit facilities will be sufficient to meet our working capital and capital expenditure requirements for this and the next year. 

 

In September 2002, our Board of Directors authorized the repurchase on the open market of up to 500,000 shares of our outstanding Common Stock at a share price no greater than $1.25, subject to compliance with applicable laws and regulations.  There is no requirement that we repurchase all or any portion of such shares.  The maximum total value of the repurchase is not to exceed $500,000.  This repurchase is to be financed with cash generated by operations.  From the inception of the repurchase authorization through the fiscal year-end date of June 30, 2003, we repurchased 75,700 shares of Common Stock for $43,741, at an average price of $0.58 per share.  Although the authority to continue the repurchase shares continues, no additional shares were repurchased in fiscal years 2004 through 2007 or to date during fiscal year 2008.

 

MAJOR CUSTOMERS

 

We had two major customers (defined as a customer that represented greater than 10% of the Company’s total revenues) in the nine months ended March 31, 2008 and 2007.  

 

 

Item 3. Controls and Procedures

 

The Chief Executive Officer and Chief Financial Officer (the principal executive officer and principal financial officer, respectively) conducted an evaluation of the design and operation of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)).  Based on that evaluation for the quarter ended March 31, 2008, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective to ensure that information required to be disclosed by use in the reports filed or submitted by us under the Exchange Act is accumulated, recorded, processed, summarized and reported to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, and to allow timely decisions regarding whether or not disclosure is required.

 

During the quarter ended March 31, 2008, there were changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.  This change is anticipated to strengthen our internal controls.  The accounting and financial reporting functions for the Carson City location were relocated to the Corporate headquarters in Santa Ana/Irvine.  This will allow the control processes and procedures to be standardized for the entire company, in addition to having one location to process payables. 

 

 

 

-23-

 

 

 

 

 

 

PART II

OTHER INFORMATION

 

Item 1.	Legal Proceedings
	The Company may be a party to various legal proceedings incidental to its business, none of which are considered by the Company to be material at this time.
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.
	None.
Item 3.	Defaults Upon Senior Securities.
	None.
Item 4.	Submissions of Matters to a Vote of Securities Holders.
	None.
Item 5.	Other Information
	On May 15, 2008, the Company and our Chief Executive Officer, Mark Murphy, entered agreed to an  amendment of the annual bonus terms of Mr. Murphy’s employment contract from “An Annual Bonus equal to (i) 0.75% of your annual salary, times (ii) each one percent (or any portion thereof) increase in pre-tax earnings (including extraordinary gains and losses) per share to  “An Annual Bonus equal to (i) 0.75% of your annual salary, times (ii) each one percent (or any portion thereof) increase in pre-tax earnings (excluding the impact of: a. extraordinary gains and losses as defined by generally accepted accounting principles, b. write-downs of goodwill, c. gains or losses on the sale of a business or product line, d. losses due to a force majure, e. change in accounting method due to a change in GAAP during its first year of application, and f. gains or losses on lawsuits unrelated to the operations of the business, but including 1. changes in balance sheet accruals for bad debts, inventory, warranty and other operational estimates, and 2. any other factor affecting pre-tax income that is not specifically excluded in a through f above) per share.”  The amendment was approved by the Company’s Board of Directors on May 15, 2008.
Item 6.	Exhibits.
	Exhibits:
		10.1	Amended and Restated Employment agreement between Pro-Dex, Inc. and Mark P. Murphy Dated May 15, 2008.
		31.1	Certifications of Chief Executive Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
		31.2	Certifications of Chief Financial Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
		32	Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

SIGNATURES

 

In accordance with the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date:  May 15, 2008   PRO-DEX INC.	Date:  May 15, 2008   PRO-DEX INC.
By: / s / Mark Murphy	By: / s / Jeffrey J. Ritchey
Mark Murphy	Jeffrey J. Ritchey
Chief Executive Officer	Secretary and Chief Financial Officer (Principal Financial and Accounting Officer)

 

 

End of Filing